Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish
Farmovs
In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19. 

The trial is expected to include more than 45 countries worldwide, including a number of South African sites. 

Farmovs

FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.   

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients. 

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.  FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.


News Archive

dti announces nominees for 2008 Science and Technology Awards
2008-10-03

 

At the announcement of the nominees for the 2008 dti Technology Awards were, from the left: Prof. Schalk Louw, Department of Zoology and Entomology, Mr Sipho Zikode, Deputy Director General at the Department of Trade and Industry (dti), Dr Romilla Maharaj, Executive Director: Human and Institutional Capacity Development at the National Research Foundation (NRF), and Mr Ephraim Baloyi, Director: Innovation and Technology at the dti.

Mr Michael Chung, master’s student in Plant Pathology, explaining some of the research conducted in the Centre for Plant Health Management (Cephma).

Prof. Schalk Louw, Department of Zoology and Entomology, and Mr Ephraim Baloyi, Director: Innovation and Technology at the dti in the Cephma laboratory.

   
dti announces nominees for 2008 Science and Technology Awards

The Department of Trade and Industry’s (dti) Deputy Director-General, Mr Sipho Zikode, yesterday announced the nominees for the 2008 dti Technology Awards which will take place on 30 and 31 October in Bloemfontein.

The purpose of these annual awards is to recognise those researchers, private institutions and students who performed well in terms of innovation and technology development, says Mr Ephraim Baloyi, Director: Innovation and Technology at the dti.

The awards are a combination of the Annual Awards of the different dti programmes supporting technology in industry. They are the Technology and Human Resources for Industry Programme (THRIP), administered by the National Research Foundation (NRF), the Support Programme for Industrial Innovation (SPII), administered by the Industrial Development Corporation, and seda Technology Programme (stp), administered by the Small Enterprise Development Agency.

The dti delegation also visited the laboratory of Prof. Schalk Louw of the UFS to view the work of this former dti Technology Awards recipient. Prof. Louw is a member of the UFS Centre for Plant Health Management (Cephma) team that won a 2007 Technology Award for groundbreaking research work on kenaf (a South African commercial fibre crop used, amongst others, in the automotive industry). The research of the Cephma team is supported by the NRF’s THRIP programme.

The awards are hosted in a different province each year to increase awareness around the dti’s technology support for researchers, small enterprises, large industries and business incubators.

Media Release
Issued by: Leonie Bolleurs
Tel: 051 401 2707
Cell: 083 645 5853
3 October 2008

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept